Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Recent Release: NASTAD, Kaiser Family Foundation Report Provides 'Inventory' Of HIV Prevention Efforts In The U.S.
The National Alliance of State and Territorial AIDS Directors and the Kaiser Family Foundation released a report that "provides the first, comprehensive inventory of HIV prevention efforts at the state and local levels" and is based on a survey of 65 state health departments, including all state and territorial jurisdictions and six U.S. cities. The report "is intended to offer a baseline picture of how HIV prevention is delivered across the country. ... " ("The National HIV Prevention Inventory: The State of HIV Prevention Across the U.S.," July 2009).
generic viagra online
First International Conference On Cancer Of Unknown Primary To Be Held London October 15
When a patient is diagnosed with metastatic disease the primary site of the cancer is usually, but not always, evident. When the origin of the cancer is not identified it is described as a Cancer of Unknown Primary site, or CUP.
News of the day
New Test For Safer Biomedical Research Results
In cancer research, as in most other biomedical sciences, they are playing a key role: living cells, kept in sterile plastic containers with red culture media populating incubators in laboratories around the world. But do researchers always know what is really living in their culture dishes? Under the microscope, different cell lines are almost impossible to distinguish from each other. When these important research objects stop growing without apparent reason - is it because of the manipulations by the scientists or because of an invisible viral or bacterial infection?
Endocrinology

St. Jude Medical Announces Australian TGA Regulatory Approval For Libra Deep Brain Stimulation Systems For Parkinson's Disease

St. Jude Medical, Inc. (NYSE:STJ) announced Australian Therapeutic Goods Administration (TGA) approval of its Libra® and LibraXP™ deep brain stimulation (DBS) systems for treating the symptoms of Parkinson"s disease, a neurological disorder that progressively diminishes a person"s control over his or her movements. Similar to a heart pacemaker, the Libra DBS systems function by delivering mild electrical pulses from an implanted device via thin wires with multiple independent electrodes. The stimulation is targeted to one of three regions in the brain which are involved in muscle control for the symptomatic treatment of Parkinson"s disease. "This approval is an important step forward in bringing our deep brain stimulation systems to a broader market," said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. "We are excited to be able to provide physicians in Australia with these best-in-class deep brain stimulation systems, allowing them to have more capability and control in treating their patients." The Libra and LibraXP neurostimulators are constant current devices that feature the largest battery capacity of any DBS device in their class, which may maximize the time between device replacement procedures. This therapy can be externally programmed by a clinician to meet individual patient needs. An estimated 6.3 million people worldwide live with Parkinson"s disease, according to the European Parkinson"s Disease Association. The disease usually develops in people between the ages of 40 and 70, with an average age of onset of 60 years. Parkinson"s disease affects both men and women in almost equal numbers, although research suggests that men are two to three times more likely to be diagnosed with the disease than women. Parkinson"s Disease Symptoms Parkinson"s disease patients may experience stiffness or rigidity of the arms and legs, slowness or lack of movement, and walking difficulties, in addition to tremor of the hands, arms, legs, jaw or face. These symptoms can make simple, everyday tasks like getting dressed, shaving, eating with utensils and drinking from a glass difficult. Faced with these challenges, Parkinson"s disease patients often have a significant decline in their quality of life. In addition to the TGA approval, the Libra and LibraXP DBS systems have also received the CE Mark approval in Europe. In the U.S., the systems are currently being evaluated in clinical studies for depression, Parkinson"s disease and essential tremor. For more information about these studies, visit http://www.BROADENstudy.com, http://www.PowerOverPD.com and http://www.PowerOverET.com St. Jude Medical


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009